- Home
- KNSA vs BGSI Comparison
KNSA vs BGSI Comparison
Compare KNSA & BGSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KNSA | BGSI |
|---|---|---|
| Founded | 2015 | 1990 |
| Country | United Kingdom | Canada |
| Employees | N/A | 13449 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.5B |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | KNSA | BGSI |
|---|---|---|
| Price | $44.90 | $122.12 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 1 |
| Target Price | $56.00 | ★ $157.00 |
| AVG Volume (30 Days) | ★ 521.2K | 47.8K |
| Earning Date | 04-28-2026 | 05-25-2026 |
| Dividend Yield | N/A | ★ 0.37% |
| EPS Growth | ★ 225.00 | N/A |
| EPS | ★ 0.75 | N/A |
| Revenue | ★ $677,564,000.00 | N/A |
| Revenue This Year | $37.60 | $35.77 |
| Revenue Next Year | $17.77 | $7.87 |
| P/E Ratio | ★ $60.48 | $231.07 |
| Revenue Growth | ★ 60.09 | N/A |
| 52 Week Low | $19.62 | $115.40 |
| 52 Week High | $50.03 | $183.10 |
Technical Indicators
Market Signals| Indicator | KNSA | BGSI |
|---|---|---|
| Relative Strength Index (RSI) | 41.91 | 35.39 |
| Support Level | $44.38 | N/A |
| Resistance Level | $45.50 | $131.30 |
| Average True Range (ATR) | 1.93 | 5.05 |
| MACD | -0.37 | 1.13 |
| Stochastic Oscillator | 10.30 | 46.23 |
Price Performance
Historical ComparisonAbout KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
About BGSI Boyd Group Services Inc.
Boyd Group Services Inc is engaged in operating non-franchised collision repair centers in North America. The Company's primary line of business is automotive collision and glass repair and related services, with the majority of revenues relating to this group of similar services. This line of business operates in Canada and the U.S. and both regions exhibit similar long-term economic characteristics. he Company is also a retail auto glass operator in the United States, under the trade names Gerber Collision & Glass, Glass America, Auto Glass Service, Auto Glass Authority. The company has majority of its sales from USA.